MMWR Morb Mortal Wkly Rep. 2019 Aug 9;68(31):679-686. doi: 10.15585/mmwr.mm6831e1.
The CDC Guideline for Prescribing Opioids for Chronic Pain recommends considering prescribing naloxone when factors that increase risk for overdose are present (e.g., history of overdose or substance use disorder, opioid dosages ≥50 morphine milligram equivalents per day [high-dose], and concurrent use of benzodiazepines). In light of the high numbers of drug overdose deaths involving opioids, 36% of which in 2017 involved prescription opioids, improving access to naloxone is a public health priority. CDC examined trends and characteristics of naloxone dispensing from retail pharmacies at the national and county levels in the United States.
CDC analyzed 2012-2018 retail pharmacy data from IQVIA, a health care, data science, and technology company, to assess U.S. naloxone dispensing by U.S. Census region, urban/rural status, prescriber specialty, and recipient characteristics, including age group, sex, out-of-pocket costs, and method of payment. Factors associated with naloxone dispensing at the county level also were examined.
The number of naloxone prescriptions dispensed from retail pharmacies increased substantially from 2012 to 2018, including a 106% increase from 2017 to 2018 alone. Nationally, in 2018, one naloxone prescription was dispensed for every 69 high-dose opioid prescriptions. Substantial regional variation in naloxone dispensing was found, including a twenty-fivefold variation across counties, with lowest rates in the most rural counties. A wide variation was also noted by prescriber specialty. Compared with naloxone prescriptions paid for with Medicaid and commercial insurance, a larger percentage of prescriptions paid for with Medicare required out-of-pocket costs.
Despite substantial increases in naloxone dispensing, the rate of naloxone prescriptions dispensed per high-dose opioid prescription remains low, and overall naloxone dispensing varies substantially across the country. Naloxone distribution is an important component of the public health response to the opioid overdose epidemic. Health care providers can prescribe or dispense naloxone when overdose risk factors are present and counsel patients on how to use it. Efforts to improve naloxone access and distribution work most effectively with efforts to improve opioid prescribing, implement other harm-reduction strategies, promote linkage to medications for opioid use disorder treatment, and enhance public health and public safety partnerships.
美国疾病控制与预防中心(CDC)发布的《慢性疼痛阿片类药物处方指南》建议,在存在增加药物过量风险的因素时,考虑开具纳洛酮处方,这些因素包括药物过量史或药物使用障碍史、阿片类药物剂量≥50 吗啡毫克当量/天(高剂量)以及苯二氮䓬类药物的同时使用。鉴于涉及阿片类药物的药物过量死亡人数众多(其中 2017 年 36%涉及处方阿片类药物),提高纳洛酮的可及性是公共卫生的当务之急。CDC 分析了美国全国和各县零售药店纳洛酮配药的趋势和特征。
CDC 分析了医疗保健、数据科学和技术公司 IQVIA 提供的 2012 年至 2018 年零售药店数据,评估了美国按美国人口普查区域、城乡状况、开方医生专业和接收者特征(包括年龄组、性别、自付费用和支付方式)的纳洛酮配药情况。还检查了与县一级纳洛酮配药相关的因素。
2012 年至 2018 年,零售药店纳洛酮处方数量大幅增加,仅 2017 年至 2018 年就增加了 106%。2018 年,全国每开出 69 张高剂量阿片类药物处方,就开出 1 张纳洛酮处方。纳洛酮的配药存在明显的区域差异,包括各县之间差异高达 25 倍,最偏远的农村县配药率最低。不同开方医生专业之间也存在较大差异。与医疗补助和商业保险支付的纳洛酮处方相比,医疗保险支付的处方需要自付费用的比例更高。
尽管纳洛酮的配药量大幅增加,但每开出一张高剂量阿片类药物处方的纳洛酮处方数量仍然很低,而且全国各地的纳洛酮配药量差异很大。纳洛酮的分发是应对阿片类药物过量流行的公共卫生应对措施的重要组成部分。当存在药物过量风险因素时,医疗保健提供者可以开具或配纳洛酮,并向患者提供如何使用的指导。为提高纳洛酮的可及性和分发而开展的工作,与改进阿片类药物的开具、实施其他减少伤害的策略、促进与治疗阿片类药物使用障碍的药物的联系以及加强公共卫生和公共安全伙伴关系的工作结合起来最为有效。